A bipartisan group of 92 members of Congress yesterday urged the Food and Drug Administration to prioritize the release of an interagency task force report on the root causes of drug shortages and recommendations to address them, noting that the number of new drug shortages rose 27% last year. “Given the detrimental impact drug shortages can have on patient care, we write to urge the FDA to prioritize the release of the Drug Shortages Task Force report,” the group said in a letter to Acting FDA Commissioner Ned Sharpless, M.D., spearheaded by Reps. Eliot Engel, D-N.Y., and Brett Guthrie, R-Ky., and supported by the AHA. Former FDA Commissioner Scott Gottlieb, M.D., convened the task force last year to receive stakeholder input on the underlying systemic causes of drug shortages and recommendations to mitigate them.
 

Related News Articles

Headline
ASHP tracked a record 323 active drug shortages during the first quarter of 2024, surpassing the previous record of 320 shortages in 2014.“Some of the most…
Headline
The Department of Health and Human Services April 2 released a white paper proposing policy solutions for Congress and others to prevent drug shortages and…
Headline
In a statement submitted to the House Ways and Means Committee for a hearing Feb. 6 on chronic drug shortages, AHA recommended Congress enact legislation to…
Headline
Reps. Doris Matsui, D-Calif., and Larry Bucshon, R-Ind., Jan. 12 introduced a House version of the Mapping America’s Pharmaceutical Supply Act, legislation…
Headline
In a statement submitted to the Senate Finance Committee Dec. 5 for a hearing on drug shortages and potential health policy solutions, AHA reiterated its…
Headline
The House Energy and Commerce Committee held a hearing on legislative proposals to prevent and respond to generic drug shortages. In comments submitted…